[Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension]
Martinez L, Paladio N
Record ID 32010000734
Catalan, English
Authors' objectives:
The main objective of this report was to review the scientific evidence available on the efficacy, safety and efficiency of ambrisentan for the treatment of patients with pulmonary arterial hypertension and to define indication criteria in the Public Hospital Utilisation Network of Catalonia.
Authors' recommendations:
After assessing the available information, ambrisentan is considered a drug comparable to other currently commercialised endothelin receptor antagonists because, given that there are no other studies that compare it with these drugs, it cannot be concluded that its efficacy or safety are inferior.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/ambrisentan_hap_aiaqs_2010ca.pdf
URL for additional information:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/ambrisentan_recomanacions_aiaqs2010ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Humans
- Hypertension, Pulmonary
- Phenylpropionates
- Pyridazines
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.